In trying to determine how profitable a company is per asset dollar, we can take a look at the firm’s Return on Assets. Return on assets is calculated by dividing a company’s net income (usually annual income) by its total assets, and is displayed as a percentage. At the time of writing, Quantum Genomics Société Anonyme (ENXTPA:ALQGC) has -1.079929 ROA. The measure is commonly used to compare the performance of businesses within the same industry, since it is very difficult for someone to obfuscate the cash flow figure. Thus, the ratio is quite a reliable and comparable measure of asset performance across an industry.

Successful stock market traders and investors don’t usually just become that way overnight. There are often many years of experience behind those winning trades. The amount of data available to investors these days is staggering. Investors have to be able to focus on the provided information and decide which data should be followed and prioritized. Many investors will be keeping a watchful eye on the next round of company earnings reports. As companies start to report quarterly numbers, investors may be able to sift through the data and make some projections on how the stock will perform over the next few quarters.

Valuation Scores

Checking in on some valuation rankings, Quantum Genomics Société Anonyme (ENXTPA:ALQGC) has a Value Composite score of 89. Developed by James O’Shaughnessy, the VC score uses five valuation ratios. These ratios are price to earnings, price to cash flow, EBITDA to EV, price to book value, and price to sales. The VC is displayed as a number between 1 and 100. In general, a company with a score closer to 0 would be seen as undervalued, and a score closer to 100 would indicate an overvalued company. Adding a sixth ratio, shareholder yield, we can view the Value Composite 2 score which is currently sitting at 92.

Quantum Genomics Société Anonyme (ENXTPA:ALQGC) has a current MF Rank of 17235. Developed by hedge fund manager Joel Greenblatt, the intention of the formula is to spot high quality companies that are trading at an attractive price. The formula uses ROIC and earnings yield ratios to find quality, undervalued stocks. In general, companies with the lowest combined rank may be the higher quality picks.

The price to book ratio or market to book ratio for Quantum Genomics Société Anonyme (ENXTPA:ALQGC) currently stands at 20.190109. The ratio is calculated by dividing the stock price per share by the book value per share. This ratio is used to determine how the market values the equity. A ratio of under 1 typically indicates that the shares are undervalued. A ratio over 1 indicates that the market is willing to pay more for the shares. There are often many underlying factors that come into play with the Price to Book ratio so all additional metrics should be considered as well.

Ever wonder how investors predict positive share price momentum? The Cross SMA 50/200, also known as the “Golden Cross” is the fifty day moving average divided by the two hundred day moving average. The SMA 50/200 for Quantum Genomics Société Anonyme (ENXTPA:ALQGC) is currently 1.33885. If the Golden Cross is greater than 1, then the 50 day moving average is above the 200 day moving average – indicating a positive share price momentum. If the Golden Cross is less than 1, then the 50 day moving average is below the 200 day moving average, indicating that the price might drop.

The Leverage Ratio of Quantum Genomics Société Anonyme (ENXTPA:ALQGC) is 0.000098. Leverage ratio is the total debt of a company divided by total assets of the current and past year divided by two. Companies take on debt to finance their day to day operations. The leverage ratio can measure how much of a company’s capital comes from debt. With this ratio, investors can better estimate how well a company will be able to pay their long and short term financial obligations.

**Volatility**

Stock volatility is a percentage that indicates whether a stock is a desirable purchase. Investors look at the Volatility 12m to determine if a company has a low volatility percentage or not over the course of a year. The Volatility 12m of Quantum Genomics Société Anonyme (ENXTPA:ALQGC) is 43.855800. This is calculated by taking weekly log normal returns and standard deviation of the share price over one year annualized. The lower the number, a company is thought to have low volatility. The Volatility 3m is a similar percentage determined by the daily log normal returns and standard deviation of the share price over 3 months. The Volatility 3m of Quantum Genomics Société Anonyme (ENXTPA:ALQGC) is 129.032000. The Volatility 6m is the same, except measured over the course of six months. The Volatility 6m is 95.858100.

**Quant Scores**

The Q.i. Value of Quantum Genomics Société Anonyme (ENXTPA:ALQGC) is 83.00000. The Q.i. Value is a helpful tool in determining if a company is undervalued or not. The Q.i. Value is calculated using the following ratios: EBITDA Yield, Earnings Yield, FCF Yield, and Liquidity. The lower the Q.i. value, the more undervalued the company is thought to be.

The Piotroski F-Score is a scoring system between 1-9 that determines a firm’s financial strength. The score helps determine if a company’s stock is valuable or not. The Piotroski F-Score of Quantum Genomics Société Anonyme (ENXTPA:ALQGC) is 1. A score of nine indicates a high value stock, while a score of one indicates a low value stock. The score is calculated by the return on assets (ROA), Cash flow return on assets (CFROA), change in return of assets, and quality of earnings. It is also calculated by a change in gearing or leverage, liquidity, and change in shares in issue. The score is also determined by change in gross margin and change in asset turnover.

The M-Score, conceived by accounting professor Messod Beneish, is a model for detecting whether a company has manipulated their earnings numbers or not. Quantum Genomics Société Anonyme (ENXTPA:ALQGC) has an M-Score of -999.000000. The M-Score is based on 8 different variables: Days’ sales in receivables index, Gross Margin Index, Asset Quality Index, Sales Growth Index, Depreciation Index, Sales, General and Administrative expenses Index, Leverage Index and Total Accruals to Total Assets. A score higher than -1.78 is an indicator that the company might be manipulating their numbers.

The Gross Margin Score is calculated by looking at the Gross Margin and the overall stability of the company over the course of 8 years. The score is a number between one and one hundred (1 being best and 100 being the worst). The Gross Margin Score of Quantum Genomics Société Anonyme (ENXTPA:ALQGC) is 8.00000. The more stable the company, the lower the score. If a company is less stable over the course of time, they will have a higher score.

Investors often conduct stock analysis to help figure out which ones are a good buy, and at what price should they get in. The two main types of stock research used by investors are fundamental and technical analysis. Some investors will only study the fundamentals while others will only follow the technicals. Many will choose to combine the two methods in order to get a more well-rounded view of the stock. Fundamental analysis entails following company data. This may include studying the balance sheet, profit and loss statements, and the overall competency of company management. Fundamental analysts often use financial ratios to help understand company information. Technical analysts often study charts in order to define trends. This research is typically not concerned with how the underlying financials of the company look, but how the stock has been trading.

Taking a look at some key metrics and ratios for Episurf Medical AB (publ) (OM:EPIS B), we note that the ROA or Return on Assets stands at -0.537445. Return on Assets shows how many dollars of earnings result from each dollar of assets the company controls. Return on assets gives an indication of the capital intensity of the company, which will also depend on the type of industry.

Traders often employ unique systems when trying to beat the stock market. There are many different trading strategies or systems that can be used. New traders may find out very quickly that trading without a plan is a recipe for ruin. When starting out, it may require a lot of focus and dedication just to stay afloat. With more experience and hard work, traders may be able to eventually scoop up some of those profits that they were expecting when they started out. Some traders may have a few big wins right out of the gate. This may lead to overconfidence in the future if the proper precautions are not taken. Traders constantly need to be paying attention to everything that is going with the stock market. Moves can happen in the blink of an eye and without any notice. Being prepared to take a position at a moment’s notice can pay off big when the opportunity arises.

In addition to ROA, there are a number of additional ratios and Quant signals available to investors in order to decipher if the shares are a good fit for their portfolio. The Shareholder Yield is a way that investors can see how much money shareholders are receiving from a company through a combination of dividends, share repurchases and debt reduction. The Shareholder Yield of Episurf Medical AB (publ) (OM:EPIS B) is -0.018887. This percentage is calculated by adding the dividend yield plus the percentage of shares repurchased. Dividends are a common way that companies distribute cash to their shareholders. Similarly, cash repurchases and a reduction of debt can increase the shareholder value, too. Another way to determine the effectiveness of a company’s distributions is by looking at the Shareholder yield (Mebane Faber). The Shareholder Yield (Mebane Faber) of Episurf Medical AB (publ) OM:EPIS B is -0.07335. This number is calculated by looking at the sum of the dividend yield plus percentage of sales repurchased and net debt repaid yield.

The EBITDA Yield is a great way to determine a company’s profitability. This number is calculated by dividing a company’s earnings before interest, taxes, depreciation and amortization by the company’s enterprise value. Enterprise Value is calculated by taking the market capitalization plus debt, minority interest and preferred shares, minus total cash and cash equivalents. The EBITDA Yield for Episurf Medical AB (publ) (OM:EPIS B) is -0.668054.

The Earnings to Price yield of Episurf Medical AB (publ) OM:EPIS B is -0.613584. This is calculated by taking the earnings per share and dividing it by the last closing share price. This is one of the most popular methods investors use to evaluate a company’s financial performance. Earnings Yield is calculated by taking the operating income or earnings before interest and taxes (EBIT) and dividing it by the Enterprise Value of the company. The Earnings Yield for Episurf Medical AB (publ) OM:EPIS B is -0.707056. Earnings Yield helps investors measure the return on investment for a given company. Similarly, the Earnings Yield Five Year Average is the five year average operating income or EBIT divided by the current enterprise value. The Earnings Yield Five Year average for Episurf Medical AB (publ) (OM:EPIS B) is -0.541613.

The Price to book ratio is the current share price of a company divided by the book value per share. The Price to Book ratio for Episurf Medical AB (publ) OM:EPIS B is 2.050221. A lower price to book ratio indicates that the stock might be undervalued. Similarly, Price to cash flow ratio is another helpful ratio in determining a company’s value. The Price to Cash Flow for Episurf Medical AB (publ) (OM:EPIS B) is -1.725296. This ratio is calculated by dividing the market value of a company by cash from operating activities. Additionally, the price to earnings ratio is another popular way for analysts and investors to determine a company’s profitability. The price to earnings ratio for Episurf Medical AB (publ) (OM:EPIS B) is -1.629769. This ratio is found by taking the current share price and dividing by earnings per share.

**Quant**

The Piotroski F-Score is a scoring system between 1-9 that determines a firm’s financial strength. The score helps determine if a company’s stock is valuable or not. The Piotroski F-Score of Episurf Medical AB (publ) (OM:EPIS B) is 2. A score of nine indicates a high value stock, while a score of one indicates a low value stock. The score is calculated by the return on assets (ROA), Cash flow return on assets (CFROA), change in return of assets, and quality of earnings. It is also calculated by a change in gearing or leverage, liquidity, and change in shares in issue. The score is also determined by change in gross margin and change in asset turnover.

The Gross Margin Score is calculated by looking at the Gross Margin and the overall stability of the company over the course of 8 years. The score is a number between one and one hundred (1 being best and 100 being the worst). The Gross Margin Score of Episurf Medical AB (publ) (OM:EPIS B) is 16.00000. The more stable the company, the lower the score. If a company is less stable over the course of time, they will have a higher score.

The ERP5 Rank is an investment tool that analysts use to discover undervalued companies. The ERP5 looks at the Price to Book ratio, Earnings Yield, ROIC and 5 year average ROIC. The ERP5 of Episurf Medical AB (publ) (OM:EPIS B) is 17253. The lower the ERP5 rank, the more undervalued a company is thought to be.

The M-Score, conceived by accounting professor Messod Beneish, is a model for detecting whether a company has manipulated their earnings numbers or not. Episurf Medical AB (publ) (OM:EPIS B) has an M-Score of -2.162412. The M-Score is based on 8 different variables: Days’ sales in receivables index, Gross Margin Index, Asset Quality Index, Sales Growth Index, Depreciation Index, Sales, General and Administrative expenses Index, Leverage Index and Total Accruals to Total Assets. A score higher than -1.78 is an indicator that the company might be manipulating their numbers.

The Value Composite One (VC1) is a method that investors use to determine a company’s value. The VC1 of Episurf Medical AB (publ) (OM:EPIS B) is 97. A company with a value of 0 is thought to be an undervalued company, while a company with a value of 100 is considered an overvalued company. The VC1 is calculated using the price to book value, price to sales, EBITDA to EV, price to cash flow, and price to earnings. Similarly, the Value Composite Two (VC2) is calculated with the same ratios, but adds the Shareholder Yield. The Value Composite Two of Episurf Medical AB (publ) (OM:EPIS B) is 95.

Many new traders will jump right into the market without any concrete plan. They may be highly optimistic, but will soon realize that it takes more than optimism to secure profits in the stock market. Successful traders are usually good at having a backup plan for every trade. This may seem unnecessary to some, but when the harsh reality of a losing trade comes into the picture, it can be hard to rebound after taking a big hit. Rushing into trades to try and cover recent losses may also leave the trader on the outside looking in. Taking a rationalized approach may help the trader ride out the bumpy patches when they inevitably come.

**Receive News & Ratings Via Email** - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.